VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to ...
– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...
The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...
EUGENE, OREGON, UNITES STATES OF AMERICA, August 13, 2024 /EINPresswire.com/ -- InVivo Biosystems, a trailblazer in the biotechnology industry, has unveiled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback